Figure 3.

Distribution of NK₁RA‐based antiemetic regimens used in the acute phase of chemotherapy‐induced nausea and vomiting (day 1) for prophylaxis of cisplatin‐based HEC (A), AC‐based HEC (B), other HEC (C), carboplatin‐based therapy (D), and any HEC and carboplatin‐based therapy (E). Percentages of patients are reported to the overall study population (n = 489,049).Note: Percentages were rounded to the closest value excluding decimals.Abbreviations: 5‐HT₃RA, 5‐hydroxytryptamine‐3 receptor antagonist; AC, anthracycline‐cyclophosphamide; DEX, dexamethasone; HEC, highly emetogenic chemotherapy; NK₁RA, neurokinin‐1 receptor antagonist.